Diligence memo · auto-generated · as of July 2, 2026
Crossbow Therapeutics, Inc.
Crossbow Therapeutics, Inc. looks over-valued against its niche peers and is active on financing cadence.
Businessfiled
Crossbow Therapeutics, Inc. operates in Biotechnology, based in Cambridge.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Crossbow Therapeutics, Inc. has raised $68M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $38M on 2023-03-29.
Most recent recorded round closed around 2025-09-17.
Valuation (modeled)modeled
Provath models Crossbow Therapeutics, Inc. at approximately $128M (range $61M–$182M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.65× the median modeled value of Series B Biotechnology companies in 2025–2027 (94 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 30 months.
Last raise 9 mo ago; this sector typically re-raises about every 14 months.
Raising on or ahead of the sector's normal rhythm.
The last round was 1.2× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 86% of Biotechnology peers (4293 compared).
Modeled value ranks above 63% of those peers.
Closest niche peers: MarvelBiome, Inc., Iantrek, Inc., Dualitas Therapeutics, Inc., Antares Therapeutics, Inc., OrthoBio Therapeutics, Inc..
Peoplefiled
10 named people on file across officers, directors and signatories.
Risks & flagsmixed
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.